Product Reports Resources Pricing Login Book a demo

Epizyme

Biotech & Life Sciences · Cambridge, United States · Founded 2007 · IPO 2013

Epizyme - Personalized Therapeutics & The Power of Epigenetics

Valuation $249M
Revenue $74M

Investors

9 investors on Epizyme's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 4 investors entered at this stage
MPM BioImpact
The Leukemia & Lymphoma Society
GSK
Kleiner Perkins
Series B+ 5 investors entered at this stage
Royalty Pharma
Baylor College of Medicine
Amgen Ventures
Bay City Capital
NEA

Global footprint

Where Epizyme has talent and traffic

Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Talent graph

The shape of Epizyme's talent

Dealroom maps Epizyme's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

DimensionScore
AI Talent Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Epizyme's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Market sentiment

What the market is saying about Epizyme

An AI-synthesized read of the highest-engagement posts about Epizyme on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Epizyme on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.